Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes Mellitus and Moderate to Severe Renal Impairment
Brief Summary: This Phase 1 study is intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of LX4211 following once daily oral administration in subjects with type 2 diabetes mellitus (T2DM) and moderate to severe renal impairment.


Options:
A: Arm Label: Treatment A; Type: EXPERIMENTAL; Interventions: Drug: LX4211 | Arm Label: LX4211 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: LX4211 Placebo | Intervention Type: DRUG; Name: LX4211; Assigned to Arm(s): Treatment A | Intervention Type: DRUG; Name: LX4211 Placebo; Assigned to Arm(s): LX4211 Placebo
B: Arm Label: Saxagliptin 2.5 mg QAM (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: metformin | Arm Label: Saxagliptin 2.5 mg titrated to 5 mg QAM (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: metformin | Arm Label: Saxagliptin 5 mg QAM (C); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: metformin | Arm Label: Saxagliptin 5 mg QPM (D); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: metformin | Arm Label: Placebo (E); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 2.5 mg QAM (A) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 2.5 mg titrated to 5 mg QAM (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 5 mg QAM (C) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 5 mg QPM (D) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (E) | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Placebo (E), Saxagliptin 2.5 mg QAM (A), Saxagliptin 2.5 mg titrated to 5 mg QAM (B), Saxagliptin 5 mg QAM (C), Saxagliptin 5 mg QPM (D)
C: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Alogliptin; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): Alogliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: dapagliflozin, Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: dapagliflozin, Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: dapagliflozin, Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Intervention Type: DRUG; Name: dapagliflozin; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: metformin hydrochloride; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: pioglitazone hydrochloride; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): 1, 2, 3, 4

Answer: A